Skin injuries associated with biological therapy in inflammatory bowel disease: beyond psoriasis

Gastroenterol Hepatol. 2022 Jan;45(1):62-63. doi: 10.1016/j.gastrohep.2020.09.003. Epub 2020 Nov 12.

[Article in English, Spanish]

Authors

Alejandro Mínguez Sabater¹, Sara Martínez Delgado², Pablo Ladrón Abia², Guillermo Bastida²

Affiliations

¹ Sección de Gastroenterología, Departamento de Medicina Digestiva, Hospital Universitario y Politécnico La Fe, Valencia, España. Electronic address: alejandromsab11@gmail.com.
² Sección de Gastroenterología, Departamento de Medicina Digestiva, Hospital Universitario y Politécnico La Fe, Valencia, España.

PMID: 33189407
DOI: 10.1016/j.gastrohep.2020.09.003

No abstract available

Publication types

Case Reports

MeSH terms

Adalimumab / therapeutic use
Adult
Antibodies, Monoclonal, Humanized / adverse effects*
Crohn Disease / drug therapy*
Drug Eruptions / etiology*
Drug Eruptions / pathology
Foot Dermatoses / chemically induced*
Foot Dermatoses / pathology
Gastrointestinal Agents / adverse effects*
Humans
Male
Psoriasis
Syphilis, Cutaneous / diagnosis
Treatment Failure
Tumor Necrosis Factor Inhibitors / therapeutic use

Substances

Antibodies, Monoclonal, Humanized
Gastrointestinal Agents
Tumor Necrosis Factor Inhibitors
vedolizumab
Adalimumab